Evaluation of urinary prostaglandin E2 metabolite as a biomarker in infants with fever due to viral infection

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 91, Issue 6, 2014, Pages 269-275

  Idborg, Helena ^a   Pawelzik, Sven Christian ^a   Perez Manso, Monica ^a   Björk, Lars ^a   Hamrin, Johan ^a   Herlenius, Eric ^a   Jakobsson, Per Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biomarker; Fever; Infants; Inflammation; Prostaglandin E2 (PGE2); Urine

Indexed keywords

CREATININE; IBUPROFEN; PARACETAMOL; PROSTAGLANDIN E2; BIOLOGICAL MARKER; PROSTAGLANDIN; TETRANOR PROSTAGLANDIN M;

ADENOVIRUS INFECTION; ARTICLE; BODY SURFACE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; FEASIBILITY STUDY; FEMALE; FEVER; HUMAN; INFANT; INFLUENZA A; LIQUID CHROMATOGRAPHY; MALE; METAPNEUMOVIRUS INFECTION; PARAINFLUENZA VIRUS INFECTION; PROSTAGLANDIN URINE LEVEL; RHINOVIRUS INFECTION; SAMPLING; SAPOVIRUS; TANDEM MASS SPECTROMETRY; METABOLISM; NEWBORN; URINE; VIROLOGY; VIRUS INFECTION;

BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; DINOPROSTONE; FEMALE; FEVER; HUMANS; INFANT; INFANT, NEWBORN; MALE; PROSTAGLANDINS; TANDEM MASS SPECTROMETRY; VIRUS DISEASES;

EID: 84922010078     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2014.09.006     Document Type: Article

References (48)

1. Ferreira S.H. Prostaglandins, aspirin-like drugs and analgesia. Nat. New Biol. 1972, 240:200-203.
2. England S., Bevan S., Docherty R.J. PGE2 modulates the tetrodotoxin-resistant sodium current in neonatal rat dorsal root ganglion neurones via the cyclic AMP-protein kinase A cascade. J. Physiol. 1996, 495:429-440. (Pt 2).
3. Vanegas H., Schaible H.G. Prostaglandins and cyclooxygenases in the spinal cord. Prog. Neurobiol. 2001, 64:327-363.
4. 2 treatment induces the synthesis of the pain-related peptide substance P and calcitonin gene-related peptide in cultured sensory ganglion explants. J. Neurochem. 2010, 115:363-372.
5. Engblom D., Saha S., Engstrom L., Westman M., Audoly L.P., Jakobsson P.J., Blomqvist A. Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis. Nat. Neurosci. 2003, 6:1137-1138.
6. Saha S., Engstrom L., Mackerlova L., Jakobsson P.J., Blomqvist A. Impaired febrile responses to immune challenge in mice deficient in microsomal prostaglandin E synthase-1. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 288:R1100-R1107.
7. Samuelsson B., Morgenstern R., Jakobsson P.J. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol. Rev. 2007, 59:207-224.
8. 2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages. Immunity 2014, 40:554-568.
9. 2: the villain in the host response to influenza virus. Immunity 2014, 40:453-454.
10. Jarabak J. Human placental 15-hydroxyprostaglandin dehydrogenase. Proc. Natl. Acad. Sci. USA 1972, 69:533-534.
11. 1 in guinea pig lung: the structures of two metabolites. J. Biol. Chem. 1964, 239:4097-4102.
12. Tai H.H., Ensor C.M., Tong M., Zhou H., Yan F. Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat. 2002, 68(69):483-493.
13. 2: an indirect index of their in vivo disposition and pharmacokinetics. J. Pharmacol. Exp. Ther. 1982, 220:229-235.
14. 1. Acta Physiol. Scand. 1966, 66:509-510.
15. 2 in man. J. Biol. Chem. 1971, 246:6713-6721.
16. Samuelsson B., Granstrom E., Green K., Hamberg M., Hammarstrom S. Prostaglandins. Annu. Rev. Biochem. 1975, 44:669-695.
17. Hamberg M. Inhibition of prostaglandin synthesis in man. Biochem. Biophys. Res. Commun. 1972, 49:720-726.
18. Seyberth H.W., Sweetman B.J., Frolich J.C., Oates J.A. Quantifications of the major urinary metabolite of the E prostaglandins by mass spectrometry: evaluation of the method's application to clinical studies. Prostaglandins 1976, 11:381-397.
19. Arai Y., Arihiro S., Matsuura T., Kato T., Matsuoka M., Saruta M., Mitsunaga M., Matsuura M., Fujiwara M., Okayasu I., Ito S., Tajiri H. Prostaglandin E-major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative colitis. Inflamm. Bowel Dis. 2014, 20:1208-1216.
20. Marnell L., Mold C., Du Clos T.W. C-reactive protein: ligands, receptors and role in inflammation. Clin. Immunol. 2005, 117:104.
21. Carter W.A., Clercq E.de Viral infection and host defense. Science 1974, 186:1172-1178.
22. De Clercq E. Interferon: ten stories in one. A short review of some of the highlights in the history of an almost quinquagenarian. Acta Microbiol. Immunol. Hung. 2005, 52:273.
23. Enocsson H., Sjöwall C., Skogh T., Eloranta M.-L., Rönnblom L., Wetterö J. Interferon-alpha mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares?. Arthritis Rheum. 2009, 60:3755.
24. Hoch B., Bernhard M., Seyberth H.W., Watzer B., Schweer H. Neonatal urinary prostanoid excretion. Prostaglandins Other Lipid Mediat. 2000, 60:9-14.
25. Murphey L.J., Williams M.K., Sanchez S.C., Byrne L.M., Csiki I., Oates J.A., Johnson D.H., Morrow J.D. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal. Biochem. 2004, 334:266-275.
26. 2, are increased in smokers. Clin. Cancer Res. 2005, 11:6087-6093.
27. Duffield-Lillico A.J., Boyle J.O., Zhou X.K., Ghosh A., Butala G.S., Subbaramaiah K., Newman R.A., Morrow J.D., Milne G.L., Dannenberg A.J. Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev. Res. 2009, 2:322-329.
28. Song W.L., Lawson J.A., Wang M., Zou H., FitzGerald G.A. Noninvasive assessment of the role of cyclooxygenases in cardiovascular health: a detailed HPLC/MS/MS method. Methods Enzymol. 2007, 433:51-72.
29. Blatnik M., Steenwyk R.C. Quantification of urinary PGEm, 6-keto PGF(1alpha) and 2,3-dinor-6-keto PGF(1alpha) by UFLC-MS/MS before and after exercise. Prostaglandins Other Lipid Mediat. 2010, 93:8-13.
30. Neale J.R., Dean B.J. Liquid chromatography-tandem mass spectrometric quantification of the dehydration product of tetranor PGE-M, the major urinary metabolite of prostaglandin E(2) in human urine. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2008, 871:72-77.
31. Zhang Y., Zhang G., Clarke P.A., Huang J.T.J., Takahashi E., Muirhead D., Steenwyk R.C., Lin Z. Simultaneous and high-throughput quantitation of urinary tetranor PGDM and tetranor PGEM by online SPE-LC-MS/MS as inflammatory biomarkers. J. Mass Spectrom.: JMS 2011, 46:705-711.
32. Medina S., Gil-Izquierdo A., Domínguez-Perles R., Cejuela-Anta R., Villaño D., Martínez-Sanz J.M., Gil P., García-Viguera C., Ferreres F., Gil J.I. Assessment of oxidative stress markers and prostaglandins after chronic training of triathletes. Prostaglandins Other Lipid Mediat. 2012, 99:79-86.
33. Song W.L., Wang M., Ricciotti E., Fries S., Yu Y., Grosser T., Reilly M., Lawson J.A., FitzGerald G.A., PGDM Tetranor An abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. J. Biol. Chem. 2008, 283:1179-1188.
34. Peters A.M., Gordon I., Sixt R. Normalization of glomerular filtration rate in children: body surface area, body weight or extracellular fluid volume?. J. Nucl. Med. 1994, 35:438-444.
35. Daham K., Song W.L., Lawson J.A., Kupczyk M., Gülich A., Dahlén S.E., FitzGerald G.A., Dahlén B. Effects of celecoxib on major prostaglandins in asthma. Clin. Exp. Allergy: J. Br. Soc. Allergy Clin. Immunol. 2011, 41:36-45.
36. Herlenius E. An inflammatory pathway to apnea and autonomic dysregulation. Respir. Physiol. Neurobiol. 2011, 178:449-457.
37. Kanashiro A., Pessini A.C., Machado R.R., Malvar D.d.C., Aguiar F.A., Soares D.M., do Vale M.L., de Souza G.E.P. Characterization and pharmacological evaluation of febrile response on zymosan-induced arthritis in rats, AJP-Regulatory. Integr. Comp. Physiol. 2009, 296:R1631-R1640.
38. Sullivan J.E., Farrar H.C. Fever and antipyretic use in children. Pediatrics 2011, 127:580-587.
39. Graham G.G., Davies M.J., Day R.O., Mohamudally A., Scott K.F. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology 2013, 21:201-232.
40. Hinz B., Cheremina O., Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 2008, 22:383-390.
41. Hofstetter A.O., Herlenius E. Interleukin-1β depresses hypoxic gasping and autoresuscitation in neonatal DBA/1lacJ mice. Respir. Physiol. Neurobiol. 2005, 146:135-146.
42. 2 pathway is a key regulator of the respiratory response to infection and hypoxia in neonates. Proc. Natl. Acad. Sci. USA 2007, 104:9894-9899.
43. Hofstetter A.O., Legnevall L., Herlenius E., Katz-Salamon M. Cardiorespiratory development in extremely preterm infants: vulnerability to infection and persistence of events beyond term-equivalent age. Acta Pædiatrica 2008, 97:285-292.
44. Drukker A., Guignard J.P. Renal aspects of the term and preterm infant: a selective update. Curr. Opin. Pediatr. 2002, 14:175-182.
45. Anderson B.J., Holford N.H. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab. Pharmacokinet. 2009, 24:25-36.
46. Hoseini R., Otukesh H., Rahimzadeh N., Hoseini S. Glomerular function in neonates. Iran. J. kidney Dis. 2012, 6:166-172.
47. Coulthard M.G., Hey E.N. Weight as the best standard for glomerular filtration in the newborn. Arch. Dis. Child. 1984, 59:373-375.
48. Leonhardt A., Busch C., Schweer H., Seyberth H.W. Reference intervals and developmental changes in urinary prostanoid excretion in healthy newborns, infants and children. Acta Paediatr. 1992, 81(1992):191-196.